论文部分内容阅读
目的探讨无血缘关系供者造血干细胞移植(UHSCT)治疗恶性血液病的疗效。方法对2003年3月至2006年12月军事医学科学院附属医院45例恶性血液病患者行UHSCT后无病存活率、移植相关病死率、移植后复发率、移植物抗宿主病(GVHD)的发生率、GVHD的严重程度及转归进行分析。结果45例患者中,3例于造血恢复前死亡。可评价的42例中,30例(71.4%)发生急性GVHD,其中Ⅱ度以上的急性GVHD9例(21.4%)。移植后复发死亡5例,感染死亡5例,GVHD相关死亡5例,现27例(64.3%)无病存活。Kaplan-Meier显示,无病存活率(58.5±13.2)%,复发率11.9%,Ⅱ度以上急性GVHD发生率21.4%。结论UHSCT治疗恶性血液病疗效肯定,为解决供者来源提供一个可选择的途径。
Objective To investigate the therapeutic effect of non-blood donor hematopoietic stem cell transplantation (UHSCT) on hematologic malignancies. Methods From March 2003 to December 2006, 45 cases of hematologic malignancies in the affiliated hospital of the Academy of Military Medical Sciences were retrospectively analyzed for disease-free survival, transplant-related mortality, post-transplant recurrence, and graft versus host disease (GVHD) Rate, the severity of GVHD and the outcome of the analysis. Results Of 45 patients, 3 died before hematopoietic recovery. Of the 42 evaluable patients, 30 (71.4%) developed acute GVHD, of which 9 (21.4%) had acute GVHD over grade II. Five patients died of recurrence after transplantation, five died of infection, five died of GVHD, and 27 (64.3%) survived without disease. Kaplan-Meier showed a disease-free survival rate (58.5 ± 13.2)%, a recurrence rate of 11.9%, and a 21.4% incidence of acute GVHD over grade Ⅱ. Conclusion UHSCT treatment of hematologic malignancies positive effect, to provide a source of alternative ways to provide.